Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Promethera Biosciences
Biotech
Roivant, Pfizer's midphase ulcerative colitis trial hits goal
Weeks after Prometheus wowed investors, Roivant has shared phase 2b data that it claims position its ex-Pfizer drug as a best-in-class contender.
Nick Paul Taylor
Jan 4, 2023 8:55am
Promethera raises €40M to fund trial of NASH cell therapy
May 6, 2019 8:00pm
Chutes & Ladders—DFCI's Haining to be VP of oncology at Merck
Oct 12, 2018 10:00am
Promethera buys TNF drug to boost cell therapy NASH strategy
Apr 10, 2018 2:00am
Promethera boosts Series C to €26M to join NASH race
Oct 28, 2016 4:06am
Promethera plans IPO to bankroll liver disease cell pipeline
Aug 24, 2016 5:52am
